Andreas Lundqvist's Group

Denna sida på svenska

Our research focuses on developing novel immunotherapy regimens for patients with cancer.

Therapies based on activating the immune system result in beneficial responses in patients with cancer. However, long-lasting clinical responses are infrequent. Our aim is to develop novel therapies based on the treatment with activated lymphocytes in patients with cancer. In order to harness the full potential of adoptive infusion of lymphocytes in patients with solid tumors, infused cells need to migrate toward the solid tumor as well as display optimal tumor killing potential. Specifically, we study how to augment the ability of T and NK cells to migrate towards and recognize solid tumors. In these projects we use several different tumor models including thyroid cancer, neuroblastoma, renal cell carcinoma, melanoma, and breast cancer. Cells within the tumor microenvironment produce an abundance of factors to impair the immune system and limit the efficacy of immunotherapy. The ability of T and NK cells to persist in the tumor microenvironment is associated with successful outcome of cancer immunotherapy. We study how T and NK cells interact with cells within the tumor microenvironment and exploit cellular and molecular mechanisms of tumor-induced immunosuppression in order to develop improved immunotherapy regimens in patients with cancer. 

Group members

Andreas Lundqvist, Group leader
Dhifaf Sarhan, Post doc
Veronika Kremer, PhD student
Kristina Witt, PhD student
Maria Wolodarski, PhD student


Erik Wennerberg, Weill Cornell Medicine, New York

Selected publications

Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience.
Murray S, Lundqvist A. 
Hum Vaccin Immunother. 2015 Sep 24:0.

Dendritic cell regulation of NK-cell responses involves lymphotoxin-α, IL-12, and TGF-β.
Sarhan D, Palma M, Mao Y, Adamson L, Kiessling R, Mellstedt H, Österborg A, Lundqvist A.
Eur J Immunol. 2015 Jun;45(6):1783-93.

CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo.
Wennerberg E, Kremer V, Childs R, Lundqvist A.
Cancer Immunol Immunother. 2015 Feb;64(2):225-35

Regulation of TRAIL-receptor expression by the ubiquitin-proteasome system.
Sarhan D, D'Arcy P, Lundqvist A.
Int J Mol Sci. 2014 Oct 14;15(10):18557-73.

Human anaplastic thyroid carcinoma cells are sensitive to NK cell-mediated lysis via ULBP2/5/6 and chemoattract NK cells.
Wennerberg E, Pfefferle A, Ekblad L, Yoshimoto Y, Kremer V, Kaminskyy VO, Juhlin CC, Höög A, Bodin I, Svjatoha V, Larsson C, Zedenius J, Wennerberg J, Lundqvist A.
Clin Cancer Res. 2014 Nov 15;20(22):5733-44.

Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.
Mao Y, Sarhan D, Steven A, Seliger B, Kiessling R, Lundqvist A.
Clin Cancer Res. 2014 Aug 1;20(15):4096-106.

A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.
Sarhan D, Wennerberg E, D'Arcy P, Gurajada D, Linder S, Lundqvist A.
Cancer Immunol Immunother. 2013 Aug;62(8):1359-68.

Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF.
Lundqvist A, Smith AL, Takahashi Y, Wong S, Bahceci E, Cook L, Ramos C, Tawab A, McCoy JP Jr, Read EJ, Khuu HM, Bolan CD, Joo J, Geller N, Leitman SF, Calandra G, Dunbar C, Kurlander R, Childs RW.
J Immunol. 2013 Dec 15;191(12):6241-9.

Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling.
Wennerberg E, Sarhan D, Carlsten M, Kaminskyy VO, D'Arcy P, Zhivotovsky B, Childs R, Lundqvist A.
Int J Cancer. 2013 Oct 1;133(7):1643-52.

Activated monocytes augment TRAIL-mediated cytotoxicity by human NK cells through release of IFN-γ.
Sarhan D, D'Arcy P, Wennerberg E, Lidén M, Hu J, Winqvist O, Rolny C, Lundqvist A.
Eur J Immunol. 2013 Jan;43(1):249-57. 

List of all publications.


  • Swedish Research Council
  • Swedish Cancer Society
  • European Research Council
  • Karolinska Institutet
  • Jeanssons Stiftelse
  • Åke Wiberg Foundation
  • Magnus Bergvall Foundation
  • Fredrik och Ingrid Thurings Foundation
  • Clas Groschinskys Foundation
  • Swedish Society of Medicine
  • Wenner-Gren Foundation
  • The American Thyroid Association
Immuno TherapyImmunology